Abstract
Acute heart failure is a major cause of emergency hospital admission, with significant impact on health resources and patient outcomes. With no new treatments for over 20 years, the advent of new innovative therapies may facilitate a radical change in our approach to such patients. In this article, we examine the current evidence for the use of current intravenous vasodilators in AHF management, and review the potential of novel therapies currently in development.
Keywords:
Acute heart failure; Nitrates; Vasodilators.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Disease
-
Administration, Intravenous
-
Atrial Natriuretic Factor / therapeutic use
-
Benzoates / therapeutic use
-
Heart Failure / drug therapy*
-
Humans
-
Natriuretic Agents / therapeutic use*
-
Natriuretic Peptide, Brain / therapeutic use
-
Natriuretic Peptides / therapeutic use
-
Nitrates / therapeutic use*
-
Peptide Fragments / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Relaxin / therapeutic use
-
Snake Venoms / therapeutic use
-
Vasodilator Agents / therapeutic use*
Substances
-
Benzoates
-
Natriuretic Agents
-
Natriuretic Peptides
-
Nitrates
-
Peptide Fragments
-
Recombinant Proteins
-
Snake Venoms
-
Vasodilator Agents
-
serelaxin protein, human
-
Natriuretic Peptide, Brain
-
BAY 58-2667
-
Ularitide
-
Atrial Natriuretic Factor
-
Relaxin
-
cenderitide